Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
NanoViricides, Inc. Common Stock
(NY:
NNVC
)
1.391
-0.009 (-0.66%)
Streaming Delayed Price
Updated: 10:50 AM EDT, Jul 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NanoViricides, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
July 01, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
June 18, 2025
Via
Investor Brand Network
Topics
Intellectual Property
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
June 18, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
June 04, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report
February 19, 2025
Via
ACCESS Newswire
NanoViricides Measles Drug Development Animal Study is Imminent
June 04, 2025
Via
ACCESS Newswire
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention
June 02, 2025
Via
AB Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
May 28, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
May 28, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
May 22, 2025
Via
Investor Brand Network
Topics
Intellectual Property
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
May 22, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
May 16, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
May 16, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
May 14, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
May 14, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC
May 08, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
May 08, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present at D. Boral Capital Inaugural Global Conference
May 05, 2025
Via
Investor Brand Network
Topics
Intellectual Property
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387
April 29, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
April 29, 2025
Via
ACCESS Newswire
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
April 14, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
March 11, 2025
Via
Investor Brand Network
Topics
Intellectual Property
World Trade
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
March 11, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
March 04, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
March 04, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
February 19, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Regulatory Compliance
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
February 11, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
February 11, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Showcases NV-387’s Broad-Spectrum Antiviral Potential at MicroCap Conference
January 29, 2025
Via
Investor Brand Network
Topics
Intellectual Property
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
January 29, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.